Literature DB >> 33380657

Decreased risk of cholangiocarcinoma in diabetic patients treated with metformin.

Pathum Sookaromdee1, Viroj Wiwanitkit2.   

Abstract

BACKGROUND: Cholangiocarcinoma is an important biliary tract cancer. The high incidence of this cancer is observed in tropical Asia. Several underlying factors are mentioned for this cancer including to diabetes mellitus. The use of the antidiabetic drug, metformin, is mentioned for possibility for decreasing risk for cholangiocarcinoma.
METHODS: The work is aimed to estimate the change in risk of local people in the endemic area of cholangiocarcinoma in scenario that diabetic patients are treated with metformin in the highly endemic area of cancer in Thailand.
RESULTS: In this study, the authors estimated the change in risk of local people in the endemic area of cholangiocarcinoma in scenario that diabetic patients are treated with metformin.
CONCLUSION: The results show a slight decreased risk of cholangiocarcinoma in that scenario.

Entities:  

Keywords:  Cholangiocarcinoma; diabetes; metformin

Mesh:

Substances:

Year:  2020        PMID: 33380657     DOI: 10.4103/jcrt.JCRT_368_18

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  1 in total

1.  Metformin Use and Survival in Patients with Advanced Extrahepatic Cholangiocarcinoma: A Single-Center Cohort Study in Fuyang, China.

Authors:  Jinqing Wu; Yabo Zhou; Guizhou Wang
Journal:  Gastroenterol Res Pract       Date:  2021-10-29       Impact factor: 2.260

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.